CR20210024A - Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 - Google Patents
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1Info
- Publication number
- CR20210024A CR20210024A CR20210024A CR20210024A CR20210024A CR 20210024 A CR20210024 A CR 20210024A CR 20210024 A CR20210024 A CR 20210024A CR 20210024 A CR20210024 A CR 20210024A CR 20210024 A CR20210024 A CR 20210024A
- Authority
- CR
- Costa Rica
- Prior art keywords
- interleukin
- inhibitors
- activity
- sulfonylurea compounds
- nlrp3
- Prior art date
Links
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La presente divulgación se refiere a compuestos de sulfonilurea y compuestos relacionados útiles en el tratamiento de un trastorno sensible a la modulación de citocinas tales como IL-1β e IL-18, modulación de NLRP3 o inhibición de la activación de NLRP3 o componentes relacionados del proceso inflamatorio</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042703 WO2020018970A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210024A true CR20210024A (es) | 2021-02-22 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210024A CR20210024A (es) | 2018-07-20 | 2019-07-19 | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (es) |
| EP (1) | EP3823726A1 (es) |
| JP (1) | JP7411631B2 (es) |
| KR (1) | KR20210034588A (es) |
| CN (1) | CN112437683A (es) |
| AR (1) | AR117617A1 (es) |
| AU (1) | AU2019305095A1 (es) |
| BR (1) | BR112021001012A2 (es) |
| CA (1) | CA3104199A1 (es) |
| CL (1) | CL2021000152A1 (es) |
| CO (1) | CO2021000817A2 (es) |
| CR (1) | CR20210024A (es) |
| IL (1) | IL280139A (es) |
| MA (1) | MA53170A (es) |
| MX (1) | MX2021000660A (es) |
| PE (1) | PE20211049A1 (es) |
| PH (1) | PH12020552155A1 (es) |
| SG (1) | SG11202012159TA (es) |
| TW (1) | TW202019937A (es) |
| WO (1) | WO2020018970A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| TW201910316A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP3707137A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| BR112021001044A2 (pt) | 2018-07-20 | 2021-04-13 | F. Hoffmann-La Roche Ag | Compostos de sulfonimidamida como inibidores da atividade de interleucina-1 |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| CA3158123A1 (en) * | 2019-11-12 | 2021-05-20 | Yonggang Wei | Amide derivative and preparation method therefore and use thereof in medicine |
| JP7843705B2 (ja) | 2020-01-22 | 2026-04-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
| IL299084A (en) | 2020-06-19 | 2023-02-01 | Ac Immune Sa | History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway |
| US20250109126A1 (en) | 2021-12-22 | 2025-04-03 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| AU2023221635A1 (en) | 2022-02-21 | 2024-09-12 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity |
| EP4554945A1 (en) | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| CA3261365A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | NEW COMPOUNDS |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| JP3573757B2 (ja) | 1997-01-29 | 2004-10-06 | ファイザー・インク | スルホニルウレア誘導体、およびインターロイキン−１の活性を制御する上でのスルホニルウレア誘導体の使用 |
| EP1214087A1 (en) | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| BR0214810A (pt) | 2001-11-30 | 2004-11-03 | Pfizer Prod Inc | Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação |
| BR112012020236A2 (pt) * | 2010-02-22 | 2016-05-17 | Raqualia Pharma Inc | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero |
| EP2781216A4 (en) | 2011-09-02 | 2015-05-27 | Kyowa Hakko Kirin Co Ltd | CHEMOKINREZEPTORAKTIVITÄTSREGLER |
| HUE055755T2 (hu) | 2015-02-16 | 2021-12-28 | Univ Queensland | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk |
| HK1257569A1 (zh) | 2016-02-16 | 2019-10-25 | The University Of Queensland | 磺醯脲和相关化合物及其用途 |
| WO2017184604A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| US11339136B2 (en) | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| KR102669722B1 (ko) | 2017-07-07 | 2024-05-29 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| SG11202001164SA (en) | 2017-08-15 | 2020-03-30 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| US11773058B2 (en) | 2017-08-15 | 2023-10-03 | Inflazome Limited | Sulfonamide carboxamide compounds |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US20210122739A1 (en) | 2017-08-15 | 2021-04-29 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| TW201910316A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| EP3707137A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| US20220267276A1 (en) | 2018-07-03 | 2022-08-25 | Novartis Ag | Nlrp modulators |
| CA3103664A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
| BR112021001044A2 (pt) | 2018-07-20 | 2021-04-13 | F. Hoffmann-La Roche Ag | Compostos de sulfonimidamida como inibidores da atividade de interleucina-1 |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| CN112672995A (zh) | 2018-08-15 | 2021-04-16 | 英夫拉索姆有限公司 | 新型磺酰胺脲化合物 |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| CN113056451A (zh) | 2018-10-24 | 2021-06-29 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| EP3914583A1 (en) | 2019-01-22 | 2021-12-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
-
2019
- 2019-07-19 CA CA3104199A patent/CA3104199A1/en active Pending
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/zh active Pending
- 2019-07-19 MA MA053170A patent/MA53170A/fr unknown
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/en active Pending
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/ko not_active Withdrawn
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/es unknown
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/es unknown
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/en not_active Ceased
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/ja active Active
- 2019-07-19 CR CR20210024A patent/CR20210024A/es unknown
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/pt not_active Application Discontinuation
- 2019-07-22 AR ARP190102054A patent/AR117617A1/es not_active Application Discontinuation
- 2019-07-22 TW TW108125890A patent/TW202019937A/zh unknown
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/es unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR117617A1 (es) | 2021-08-18 |
| PE20211049A1 (es) | 2021-06-04 |
| SG11202012159TA (en) | 2021-01-28 |
| US20210261568A1 (en) | 2021-08-26 |
| EP3823726A1 (en) | 2021-05-26 |
| JP2021530536A (ja) | 2021-11-11 |
| WO2020018970A1 (en) | 2020-01-23 |
| IL280139A (en) | 2021-03-01 |
| AU2019305095A1 (en) | 2020-12-17 |
| MA53170A (fr) | 2021-05-26 |
| CA3104199A1 (en) | 2020-01-23 |
| US11560391B2 (en) | 2023-01-24 |
| TW202019937A (zh) | 2020-06-01 |
| MX2021000660A (es) | 2021-03-25 |
| CO2021000817A2 (es) | 2021-02-17 |
| BR112021001012A2 (pt) | 2021-04-20 |
| KR20210034588A (ko) | 2021-03-30 |
| JP7411631B2 (ja) | 2024-01-11 |
| CL2021000152A1 (es) | 2021-07-09 |
| CN112437683A (zh) | 2021-03-02 |
| PH12020552155A1 (en) | 2021-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210022A (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 | |
| PH12020552155A1 (en) | Sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| PH12019501611A1 (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| PH12022550098A1 (en) | Parp1 inhibitors | |
| MX2022009308A (es) | Compuestos y usos de estos. | |
| MX2022009366A (es) | Compuestos y usos de estos. | |
| PH12022550165A1 (en) | Interleukin-2 agents and uses thereof | |
| WO2021022163A3 (en) | Compounds and uses thereof | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| MX2025015277A (es) | Inhibidores de masp-2 y metodos de uso | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| MY197094A (en) | Sulfonylureas and related compounds and use of same | |
| MY209468A (en) | Masp-2 inhibitors and methods of use | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| EP4691567A3 (en) | Jak1 pathway inhibitor for use in the treatment of chronic lung allograft dysfunction | |
| ZA202409281B (en) | Masp-2 inhibitors and methods of use | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| PH12017501980A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
| EP4706394A3 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| PH12019500479A1 (en) | Compositions for treating dementia | |
| MY205163A (en) | Silylethynyl hetaryl compounds as nitrification inhibitors | |
| PH12022551548A1 (en) | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof |